Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1994 1
1995 3
1996 2
1997 2
1998 1
1999 1
2000 1
2003 3
2004 2
2005 2
2006 2
2007 2
2008 2
2009 8
2010 6
2011 3
2012 1
2014 2
2015 3
2016 2
2017 4
2018 3
2020 4
2021 4
2022 1
2023 1
2024 6
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E, Camus V, Thieblemont C, Sibon D, Casasnovas RO, Ysebaert L, Damaj G, Guidez S, Pica GM, Kim WS, Lim ST, André M, García-Sancho AM, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Re A, Gaulard P, Delfau-Larue MH, de Leval L, Meignan M, Li J, Morschhauser F, Delarue R. Bachy E, et al. Among authors: penarrubia mj. J Clin Oncol. 2022 Jan 20;40(3):242-251. doi: 10.1200/JCO.21.01815. Epub 2021 Nov 29. J Clin Oncol. 2022. PMID: 34843406 Clinical Trial.
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas RO, Ysebaert L, Damaj GL, Guidez S, Pica GM, Kim WS, Lim ST, Andre M, Gutiérrez N, Penarrubia MJ, Staber PB, Trotman J, Hüttmann A, Stefoni V, Tucci A, Fogarty P, Farhat H, Abraham J, Abarah W, Belmecheri F, Ribrag V, Delfau-Larue MH, Cottereau AS, Itti E, Li J, Delarue R, de Leval L, Morschhauser F, Bachy E. Camus V, et al. Among authors: penarrubia mj. J Clin Oncol. 2024 May 10;42(14):1612-1618. doi: 10.1200/JCO.23.01687. Epub 2024 Feb 16. J Clin Oncol. 2024. PMID: 38364196 Clinical Trial.
Liquid biopsy for molecular characterization of diffuse large B-cell lymphoma and early assessment of minimal residual disease.
Alcoceba M, Stewart JP, García-Álvarez M, Díaz LG, Jiménez C, Medina A, Chillón MC, Gazdova J, Blanco O, Díaz FJ, Peñarrubia MJ, Fernández S, Montes C, Cabero A, Caballero MD, García-Sanz R, González M, González D, Tamayo P, Gutiérrez NC, García-Sancho AM, Sarasquete ME. Alcoceba M, et al. Among authors: penarrubia mj. Br J Haematol. 2024 Jul;205(1):109-121. doi: 10.1111/bjh.19458. Epub 2024 May 29. Br J Haematol. 2024. PMID: 38811363
Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.
Rey-Búa B, Grande C, Sánchez Blanco JJ, Abrisqueta P, Gutiérrez A, Ramírez Páyer Á, Giné E, Zeberio Etxetxipia I, Terol MJ, de la Cruz Vicente F, Andreu R, Ramirez MJ, de la Fuente A, Viguria MC, Peñarrubia MJ, Jiménez-Ubieto A, Montes-Moreno S, López-Guillermo A, Caballero MD, Martín García-Sancho A. Rey-Búa B, et al. Among authors: penarrubia mj. Clin Cancer Res. 2024 Sep 3;30(17):3704-3714. doi: 10.1158/1078-0432.CCR-24-0183. Clin Cancer Res. 2024. PMID: 38900037 Clinical Trial.
Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity.
Moreno-Arciniegas A, García A, Kelm M, D'Amore F, da Silva MG, Sánchez-González J, Sánchez PL, López-Fernández T, Córdoba R, Asteggiano R, Camus V, Smink J, Ferreira A, Kersten MJ, Bolaños N, Escalera N, Pacella E, Gómez-Talavera S, Quesada A, Rosselló X, Ibanez B; RESILIENCE Trial Investigators. Moreno-Arciniegas A, et al. Eur J Heart Fail. 2024 Oct;26(10):2213-2222. doi: 10.1002/ejhf.3395. Epub 2024 Aug 30. Eur J Heart Fail. 2024. PMID: 39212445
Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis.
Marín-Quílez A, Di Buduo CA, Díaz-Ajenjo L, Abbonante V, Vuelta E, Soprano PM, Miguel-García C, Santos-Mínguez S, Serramito-Gómez I, Ruiz-Sala P, Peñarrubia MJ, Pardal E, Hernández-Rivas JM, González-Porras JR, García-Tuñón I, Benito R, Rivera J, Balduini A, Bastida JM. Marín-Quílez A, et al. Among authors: penarrubia mj. Blood. 2023 Jan 26;141(4):406-421. doi: 10.1182/blood.2022016995. Blood. 2023. PMID: 36395340 Free PMC article.
Unbiased immunome characterisation correlates with COVID-19 mRNA vaccine failure in immunocompromised adults.
H-Vázquez J, Cal-Sabater P, Arribas-Rodríguez E, Fiz-López A, Perez-Segurado C, Martín-Muñoz Á, De Prado Á, Perez Mazzali M, de Castro CG, Del Hierro AG, de la Fuente Graciani I, Pérez González S, Gutiérrez S, Tellería P, Novoa C, Rojo Rello S, Garcia-Blesa A, Sedano R, Martínez García AM, Garcinuño Pérez S, Domínguez-Gil M, Hernán García C, Guerra MM, Muñoz-Sánchez E, Barragan-Pérez C, Diez Morales S, Casazza Donnarumma O, Ramos Pollo D, Santamarta Solla N, Álvarez Manzanares PM, Bravo S, García Alonso C, Avendaño Fernández LA, Gay Alonso J, Garrote JA, Arranz E, Eiros JM, Rescalvo Santiago F, Quevedo Villegas C, Tamayo E, Orduña A, Dueñas C, Peñarrubia MJ, Cuesta-Sancho S, Montoya M, Bernardo D. H-Vázquez J, et al. Among authors: penarrubia mj. Front Immunol. 2024 Nov 14;15:1405217. doi: 10.3389/fimmu.2024.1405217. eCollection 2024. Front Immunol. 2024. PMID: 39611158 Free PMC article.
Emphysematous gastritis and severe aplastic anemia.
Gutierrez O, Cantalapiedra A, Tabuyo MI, Del Villar R, Peñarrubia MJ, Sales R, García-Frade LJ. Gutierrez O, et al. Among authors: penarrubia mj. Hematol J. 2003;4(1):82-4. doi: 10.1038/sj.thj.6200200. Hematol J. 2003. PMID: 12692527 Review.
New therapies for relapsed or refractory aggressive B-cell lymphoma increase survival: Analysis from the RELINF registry of the GELTAMO group.
Bastos-Oreiro M, Abrisqueta P, Gutierrez A, Jiménez Ubieto A, Poza M, Fernanez-Caldas P, LLacer MJ, Gonzalez de Villambrosia S, Córdoba R, López A, Ceballos E, Navarro B, Muntañola A, Donato E, Diez-Baeza E, Escoda L, Luzardo H, Peñarrubia MJ, García Belmonte D, Pardal E, Lozada C, Martín García-Sancho A. Bastos-Oreiro M, et al. Among authors: penarrubia mj. Hemasphere. 2024 Apr 22;8(4):e70. doi: 10.1002/hem3.70. eCollection 2024 Apr. Hemasphere. 2024. PMID: 38650598 Free PMC article. No abstract available.
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Ribera JM, Morgades M, Ciudad J, Montesinos P, Esteve J, Genescà E, Barba P, Ribera J, García-Cadenas I, Moreno MJ, Martínez-Carballeira D, Torrent A, Martínez-Sánchez P, Monsalvo S, Gil C, Tormo M, Artola MT, Cervera M, González-Campos J, Rodríguez C, Bermúdez A, Novo A, Soria B, Coll R, Amigo ML, López-Martínez A, Fernández-Martín R, Serrano J, Mercadal S, Cladera A, Giménez-Conca A, Peñarrubia MJ, Abella E, Vall-Llovera F, Hernández-Rivas JM, Garcia-Guiñon A, Bergua JM, de Rueda B, Sánchez-Sánchez MJ, Serrano A, Calbacho M, Alonso N, Méndez-Sánchez JÁ, García-Boyero R, Olivares M, Barrena S, Zamora L, Granada I, Lhermitte L, Feliu E, Orfao A. Ribera JM, et al. Among authors: penarrubia mj. Blood. 2021 Apr 8;137(14):1879-1894. doi: 10.1182/blood.2020007311. Blood. 2021. PMID: 33150388 Free article. Clinical Trial.
69 results